ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.

Trial Details

NCT ID
NCT06254326
Phase
PHASE1
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • TTRNA-DC vaccines with GM-CSF
  • Autologous Hematopoietic Stem cells (HSCs)
  • TTRNA-xALT
  • Td vaccine
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483

Key Eligibility Criteria

  • Male or female, aged 18 years and above
  • Tumor tissue obtained on a screening consent is available.
  • Confirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted Oligodendroglioma WHO grade 2 or WHO grade 3, more than 12 weeks from completion …
  • Karnofsky Performance Status ≥ 60

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →